Literature DB >> 9247511

Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators.

A F van den Heuvel1, W H van Gilst, D J van Veldhuisen, R J de Vries, P H Dunselman, J H Kingma.   

Abstract

OBJECTIVES: This study was conducted to test the hypothesis that angiotensin-converting enzyme (ACE) inhibition reduces myocardial ischemia and related events after myocardial infarction (MI).
BACKGROUND: The oxygen demand/supply ratio of the myocardium is influenced by angiotensin II as a result of its arterial vasoconstrictive and inotropic effects and through its interaction with the sympathetic nervous system.
METHODS: We studied 244 patients who had been included in a double-blind, randomized, placebo-controlled, post-MI, ACE inhibition intervention study (Captopril and Thrombolysis Study [CATS]). All patients underwent exercise testing before and 3 and 12 months after hospital discharge. After 1-year double-blind treatment, all patients continued receiving single-blind placebo for 1 month.
RESULTS: Total exercise time increased in both groups after 3 months (placebo: +86 +/- 13 s; captopril: +69 +/- 12 s, p = 0.8 between groups) and increased further after 1 year (placebo: +13 +/- 11 s; captopril: +33 +/- 13 s, p = 0.7 between groups). There were also no differences in mean ST segment depression. During the 12 months, significantly fewer ischemia-related events occurred in the captopril group (82 vs. 52, p = 0.015). This difference was found between 3 and 12 months but not during the first 3 months. After withdrawal from double-blind medication, nine ischemic events were reported in teh captopril group compared with one in the placebo group (p = 0.006 between groups).
CONCLUSIONS: The present data show that captopril may reduce the incidence of ischemia-related events after MI, which becomes apparent after 3 months. However, no anti-ischemic effect was observed during exercise testing. After withdrawal from ACE inhibition, a high incidence of clinical events occurred, suggesting a rebound phenomenon.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247511     DOI: 10.1016/s0735-1097(97)00183-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

2.  Angiotensin-converting enzyme inhibitor therapy affects myocardial fatty acid metabolism after acute myocardial infarction.

Authors:  S Fukuzawa; S Ozawa; M Inagaki; J Sugioka; M Daimon; S Kushida
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

3.  Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril.

Authors:  A F van den Heuvel; P K Blanksma; H M Siebelink; L M van Wijk; F Boomsma; W Vaalburg; H J Crijns; D J van Veldhuisen
Journal:  Int J Cardiovasc Imaging       Date:  2001-10       Impact factor: 2.357

4.  No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months.

Authors:  Ronnie Willenheimer; Steen Juul-Möller; Lennart Forslund; Leif Erhardt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

5.  Captopril Pretreatment Produces an Additive Cardioprotection to Isoflurane Preconditioning in Attenuating Myocardial Ischemia Reperfusion Injury in Rabbits and in Humans.

Authors:  Yi Tian; Haobo Li; Peiyu Liu; Jun-mei Xu; Michael G Irwin; Zhengyuan Xia; Guogang Tian
Journal:  Mediators Inflamm       Date:  2015-07-27       Impact factor: 4.711

6.  RAS inhibition and COVID-19: more questions than answers?

Authors:  Mathieu Kerneis; Gilles Montalescot
Journal:  Lancet Respir Med       Date:  2021-06-11       Impact factor: 30.700

7.  Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis.

Authors:  Mathieu Kerneis; Arnaud Ferrante; Paul Guedeney; Eric Vicaut; Gilles Montalescot
Journal:  Arch Cardiovasc Dis       Date:  2020-10-22       Impact factor: 2.340

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.